Recruiting

Comparing two immune-suppressing medications after stem cell transplant for blood cancers

Plain-English translation of NCT06895538 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated June 2026 · How we translate trials

Read our Leukemia research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial compares two immune-suppressing medications given during stem cell transplant for patients with blood cancers like leukemia, lymphoma, or myelodysplastic syndrome. The study is testing whether ATLG (a newer medication) works better and causes fewer serious infections than ATG (the standard medication used today). Both medications help prevent the transplanted immune cells from attacking the patient's body after transplant.

While the standard medication (ATG) has helped many patients, research suggests it may increase the risk of serious viral infections like cytomegalovirus after transplant. Early evidence shows that this newer medication might reduce those infection risks, so doctors want to test whether it truly offers a safer option.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with a blood cancer (such as leukemia, lymphoma, or myelodysplastic syndrome) confirmed by a biopsy or blood test
this is your first stem cell transplant from a donor
your heart, lungs, liver, and kidneys are working well enough for transplant (based on specific blood tests and heart scans)
you are expected to survive at least 12 weeks beyond the transplant

You likely don't qualify if…

you have received ATG, ALG, or ATLG in the past six months
you are allergic to any ingredient in either medication
you have a serious infection (bacterial, viral, or other) that is not controlled by treatment
you are pregnant, breastfeeding, or unwilling to use effective birth control during the trial
you are enrolled in another clinical trial involving an experimental drug or device

What participation looks like

If you qualify, you will receive one of the two immune-suppressing medications as part of your conditioning regimen before your stem cell transplant. The medication will be given intravenously (through a vein) in the days before you receive the transplant. You will be monitored closely during and after the transplant to track how well your new immune system develops and whether you experience any infections or other side effects. The study involves 24 patients total and will track your recovery over time.

Comparing two immune-suppressing medications after stem cell transplant for blood cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)